We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    AG-348

A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02476916
First Posted: June 22, 2015
Last Update Posted: June 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.
  Purpose
Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 in patients with PK deficiency.

Condition Intervention Phase
Pyruvate Kinase Deficiency Drug: AG-348 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Resource links provided by NLM:


Further study details as provided by Agios Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Safety: incidence of adverse events [ Time Frame: 24 weeks, on average ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters of AG-348 and its metabolite area-under-the-curve (AUC) 0-12hr [ Time Frame: 24 weeks ]
  • Pharmacokinetic parameters of AG-348 and its metabolite (Tmax) [ Time Frame: 24 weeks ]
  • Pharmacokinetic parameters of AG-348 and its metabolite (Cmax) [ Time Frame: 24 weeks ]
  • Pharmacokinetic parameters of AG-348 and its metabolite (Cl/F) [ Time Frame: 24 weeks ]
  • Change from baseline in whole blood concentration of adenosine triphosphate (ATP) [ Time Frame: 24 weeks ]
  • Change from baseline in whole blood concentration of 2,3 - diphosphoglycerate (2,3-DPG) [ Time Frame: 24 weeks ]
  • Change from baseline in hemoglobin. [ Time Frame: 24 weeks ]

Enrollment: 52
Study Start Date: June 2015
Estimated Study Completion Date: May 2019
Primary Completion Date: May 8, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: higher fixed dose
multiple doses of AG-348.
Drug: AG-348
A range of doses of AG-348 will be tested based on the assessment of safety, tolerability and clinical efficacy. AG-348 will be administered by mouth (orally) each day for a period of 24 weeks.
Experimental: Arm 2: lower fixed dose
multiple doses of AG-348.
Drug: AG-348
A range of doses of AG-348 will be tested based on the assessment of safety, tolerability and clinical efficacy. AG-348 will be administered by mouth (orally) each day for a period of 24 weeks.
Experimental: Arm 3: not yet determined
A range of doses of AG-348 will be tested based on the assessment of safety, tolerability and efficacy.
Drug: AG-348
A range of doses of AG-348 will be tested based on the assessment of safety, tolerability and clinical efficacy. AG-348 will be administered by mouth (orally) each day for a period of 24 weeks.

Detailed Description:
This is a Phase 2, open label, two arm, multicenter, randomized, dose-ranging study during which adult patients with PK deficiency will receive multiple doses of AG-348 for up to 24 weeks (Core Period); eligible patients may enter an Extension Period to receive AG-348 for up to 2 additional years. Up to 25 patients will be randomized to two doses of AG-348; a third arm (up to 25 patients) may be added, if required. AG-348 will be administered orally at various doses; if implemented, the dose of Arm 3 will be determined based on ongoing review. Data will be reviewed on a regular basis and study design, dose and schedule will be adapted based on these reviews. The study will evaluate the safety and tolerability of multiple doses of AG-348, pharmacokinetic (PK) and pharmacodynamic (PD) profile of AG-348 and early indicators of clinical efficacy.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Informed consent
  2. Male or female, aged 18 years and older
  3. Known medical history of PK deficiency
  4. PK deficiency confirmed by enzymatic assay at Screening
  5. Genotypic characterization of PKR gene at Screening
  6. Genotypic characterization of uridine-5'-diphosphate-glucuronyltransferase-A1 (UGTA1) gene to document underlying Gilbert's disease (Gilbert's disease pts are eligible)
  7. Males Hb ≤ 12.0 g/dL, females Hb ≤ 11 g/dL
  8. Transfusion independent, defined as no more than 3 units of red blood cells (RBC) transfused in 12 months prior to the first day of study dosing and no transfusions within 4 months of first day of study dosing
  9. Splenectomized patients must have had the procedure at least 6 months prior to Screening and must be up-to-date in recommended vaccinations
  10. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  11. Must be taking at least 1 mg folic acid daily in the 21 days prior to screening
  12. Adequate organ function defined by liver function, kidney function, platelet count and coagulation assessments
  13. Agreement to use approved contraceptive measures
  14. Women must not be breastfeeding

    For entry into the Extension Period, patients must meet criteria # 15-16:

  15. Must have completed 24 weeks of treatment during the Core Period and tolerated AG-348
  16. The treating Investigator agrees that there is a potential for clinical benefit to continued treatment and recommends participation in the Extension Period and the Medical Monitor approves

Exclusion criteria

  1. Hb ˃ 12.0 g/dL if male, Hb ˃11.0 g/dL if female
  2. Additional diagnosis of other congenital or acquired blood disorder
  3. Iron overload sufficiently severe to result in cardiac, hepatic or pancreatic insufficiency
  4. Bone marrow or stem cell transplant
  5. Clinically symptomatic cholelithiasis or cholecystitis
  6. Currently enrolled in any other investigational trial. Participation in the PK Deficiency Natural History Study (NCT02053480) is permitted
  7. Exposure to any investigational drug, device or procedure within 28 days prior to screening or during trial participation
  8. Concurrent medical condition such as poorly controlled hypertension, heart failure, active infection, frequent post-splenectomy sepsis, Hepatitis B or C, Human Immunodeficiency Virus type 1 (HIV1) or Human Immunodeficiency Virus type 2 (HIV2) infection, poorly controlled diabetes mellitus, history of primary malignancy with the exception of curatively treated nonmelanomatous skin cancer, cervical cancer of breast cancer in situ
  9. Major surgery in the last 6 months
  10. Psychiatric disorder that could compromise the ability of the patient to cooperate with the study
  11. Serum bilirubin higher to the upper limit of normal attributable to factors other than hemolysis or Gilbert's Syndrome
  12. Use of restricted products known to strongly inhibit cytochrome P450 (CYP) 3A4 metabolism within 5 days prior to Prior Day 1 dosing, or to strongly induce cytochrome P450 3A4 (CYP3A4) metabolism within 28 days prior to Day 1 dosing, or to strongly inhibit P-glycoprotein transporter within 5 days prior to Day 1 dosing, or digoxin within 5 days prior to Day 1 dosing.
  13. Heart-rate corrected QT interval - Fridericia's method (QTcF) interval ˃ 450 ms in male, QTcF > 470 ms in female, with the exception of patients with a left Bundle Branch Block
  14. Cardiac arrhythmias that are clinically significant or treated with drugs that are substrates of CYP3A4
  15. Allergy to sulfonamides if characterized by acute hemolytic anemia, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson Syndrome
  16. Any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to participate in the study
  17. Patients will not be permitted to enter the Extension Period if: The patient experienced AEs during the Core Period that are considered by the treating Investigator or the Sponsor's designated Medical Monitor to pose a significant safety risk to the patient if treatment were to be extended
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02476916


Locations
United States, California
Stanford University
Palo Alto, California, United States, 94304
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02215
United States, Michigan
Wayne State University School of Medicine - Children's Hospital of Michigan
Detroit, Michigan, United States, 48201
United States, New York
New York Presbyterian Hospital- Weil Cornell Medical College
New York, New York, United States, 10065
United States, Pennsylvania
Central Pennsylvania Clinic
Belleville, Pennsylvania, United States, 17004
Children Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States, 19104
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84113
Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2C4
France
Hôpital de la Timone
Marseille, Bouches-du-Rhône, France, 13385
Hôpital Henri Mondor
Créteil, Ile-de-France, France, 94010
Hôpital Saint-Vincent de Paul
Lille, Nord, France, 59000
Italy
UOC Oncoematologia Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milano, Italy, 20122
Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 3584 CX
United Kingdom
Hammersmith Hospital
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Agios Pharmaceuticals, Inc.
  More Information

Responsible Party: Agios Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02476916     History of Changes
Other Study ID Numbers: AG348-C-003
First Submitted: June 10, 2015
First Posted: June 22, 2015
Last Update Posted: June 29, 2017
Last Verified: November 2016

Keywords provided by Agios Pharmaceuticals, Inc.:
Pyruvate Kinase Deficiency
Hemolytic anemia
Protein Kinase R (PKR)
Drive PK

Additional relevant MeSH terms:
Anemia, Hemolytic, Congenital Nonspherocytic
Pyruvate Metabolism, Inborn Errors
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Genetic Diseases, Inborn
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases